Company Seeks to Expand mRNA’s Reach in Cystic Fibrosis: A Path Toward New Treatment Possibilities

We assign a 58.6% overall probability partners will report positive data from phase I/II trial.

Today's report is on a biotechnology firm’s messenger RNA platform that, while originally developed for an innovative immunization, has also been adapted by a partner company to address cystic fibrosis. This approach seeks to deliver a key protein directly to the lungs, targeting individuals who currently lack effective treatment options. Over the years, the partner has introduced multiple therapies for this genetic disease, substantially benefiting a large portion of those affected. Despite initial hurdles using the messenger RNA delivery system, the new therapy showed enough promise to advance into an early clinical study, where there is measured optimism for positive results. Cystic fibrosis is an inherited condition that progressively impacts lung function and can also affect the pancreas and other organs.

We assign a 58.6% overall probability the partners will report positive data from its phase I/II trial.

MACE Scores are based on:

• Market Demand

• Adoption by payers and key opinion leaders (KOLs)

• Clinical progress

• Experience and capital.